Lung cancer genotype-based therapy and predictive biomarkers present and future

Keyphrases

• Pathologist 100%
• Genotype 100%
• Lung Cancer 100%
• Predictive Biomarker 100%
• Tyrosine Kinase Inhibitor 66%
• Precision Medicine 66%
• Immunohistochemistry 33%
• Lung Cancer Patients 33%
• Clinical Response 33%
• Activating mutation 33%
• Acquired Resistance 33%
• Non-small Cell Lung Cancer (NSCLC) 33%
• Epidermal Growth Factor Receptor 33%
• Background Current 33%
• Fusion Partner 33%
• Next-generation Antibodies 33%
• Druggable Targets 33%
• Molecular Targeted Therapy 33%
• Peer-reviewed Literature 33%
• Clinical Background 33%
• Second-generation Tyrosine Kinase Inhibitors 33%
• Anaplastic Lymphoma Kinase Rearrangement 33%
• Next-generation Genotyping 33%

Medicine and Dentistry

• Biological Marker 100%
• Lung Cancer 100%
• Pathologist 75%
• Tyrosine-Kinase Inhibitor 75%
• Personalized Medicine 50%
• Disease 25%
• Immunohistochemistry 25%
• Molecularly Targeted Therapy 25%
• Epidermal Growth Factor Receptor 25%
• Non Small Cell Lung Cancer 25%
• Anaplastic Lymphoma Kinase 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Biological Marker 100%
• Lung Cancer 100%
• Protein Tyrosine Kinase Inhibitor 75%
• Disease 25%
• Non Small Cell Lung Cancer 25%
• Epidermal Growth Factor Receptor 25%
• Anaplastic Lymphoma Kinase 25%